Literature DB >> 11952722

Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia.

F M Brunkhorst1, B Al-Nawas, F Krummenauer, Z F Forycki, P M Shah.   

Abstract

OBJECTIVE: Procalcitonin (PCT) is a peptide that is found elevated in patients with sepsis and severe infections. In healthy persons PCT serum levels are below 0.1 ng/mL. The aim of this study was to investigate the value of serum PCT determination for risk evaluation in patients with pneumonia.
METHODS: We focused on the correlation of PCT with the clinical status of the patient and prognosis of the disease. In a prospective study, in a nonsurgical intensive care unit the following parameters were assessed regularly in 93 patients with documented pneumonia: C-reactive protein (CRP), white blood cell count (WBC), body temperature, PCT and Acute Physiology and Chronic Health Evaluation (APACHE) II score.
RESULTS: At the onset of infection 50% of the patients had elevated PCT levels above 2 ng/mL. The model of multivariate analysis of all tested parameters on days 0-5 stratified for clinical outcome (change in clinical classification or death) showed local significance for APACHE II score only. None of the other parameters in this model serves as an isolated indicator for change of clinical status or death. An intra-individual change of body temperature or CRP was never significantly associated with a change in the clinical status of the patient.
CONCLUSION: Change in PCT on admission and at the end of the observation period significantly indicated a clinical change.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11952722     DOI: 10.1046/j.1469-0691.2002.00349.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  23 in total

1.  Legionella pneumonia and serum procalcitonin.

Authors:  Laura Franzin; Daniela Cabodi
Journal:  Curr Microbiol       Date:  2004-10-28       Impact factor: 2.188

2.  Biomarkers for community-acquired pneumonia in the emergency department.

Authors:  Todd A Florin; Lilliam Ambroggio
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

3.  Serial changes in soluble triggering receptor expressed on myeloid cells in the lung during development of ventilator-associated pneumonia.

Authors:  Rogier M Determann; Julian L Millo; Sébastien Gibot; Johanna C Korevaar; Margreeth B Vroom; Tom van der Poll; Christopher S Garrard; Marcus J Schultz
Journal:  Intensive Care Med       Date:  2005-09-30       Impact factor: 17.440

Review 4.  [Assessment, triage, and follow-up of a patient with: acute CAP COPD].

Authors:  K Faure
Journal:  Med Mal Infect       Date:  2006-11-07       Impact factor: 2.152

5.  Performance evaluation of MR-proadrenomedullin and other scoring systems in severe sepsis with pneumonia.

Authors:  Serdar Akpinar; Kazım Rollas; Ali Alagöz; Fatih Seğmen; Tuğrul Sipit
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

6.  Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ.

Authors:  Stefan Krüger; Santiago Ewig; Jana Papassotiriou; Jan Kunde; Reinhard Marre; Heike von Baum; Norbert Suttor; Tobias Welte
Journal:  Respir Res       Date:  2009-07-12

Review 7.  Improving outcomes of elderly patients with community-acquired pneumonia.

Authors:  Félix Gutiérrez; Mar Masiá
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

8.  Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia.

Authors:  Charles-Edouard Luyt; Alain Combes; Catherine Reynaud; Guillaume Hekimian; Ania Nieszkowska; Marc Tonnellier; Alexandra Aubry; Jean-Louis Trouillet; Maguy Bernard; Jean Chastre
Journal:  Intensive Care Med       Date:  2008-04-18       Impact factor: 17.440

9.  Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study.

Authors:  S Schroeder; M Hochreiter; T Koehler; A-M Schweiger; B Bein; F S Keck; T von Spiegel
Journal:  Langenbecks Arch Surg       Date:  2008-11-26       Impact factor: 3.445

10.  Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia.

Authors:  Nicolas Boussekey; Olivier Leroy; Serge Alfandari; Patrick Devos; Hugues Georges; Benoit Guery
Journal:  Intensive Care Med       Date:  2006-02-14       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.